Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.33
PRXL's Cash-to-Debt is ranked lower than
82% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.94 vs. PRXL: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PRXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 3.13 Max: No Debt
Current: 0.33
Equity-to-Asset 0.24
PRXL's Equity-to-Asset is ranked lower than
84% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. PRXL: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
PRXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.45 Max: 0.72
Current: 0.24
0.24
0.72
Interest Coverage 24.00
PRXL's Interest Coverage is ranked lower than
58% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 55.24 vs. PRXL: 24.00 )
Ranked among companies with meaningful Interest Coverage only.
PRXL' s Interest Coverage Range Over the Past 10 Years
Min: 3.16  Med: 6.29 Max: 28.15
Current: 24
3.16
28.15
Piotroski F-Score: 7
Altman Z-Score: 3.21
Beneish M-Score: -2.47
WACC vs ROIC
7.78%
18.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 10.19
PRXL's Operating Margin % is ranked higher than
68% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. PRXL: 10.19 )
Ranked among companies with meaningful Operating Margin % only.
PRXL' s Operating Margin % Range Over the Past 10 Years
Min: 5.49  Med: 6.55 Max: 10.19
Current: 10.19
5.49
10.19
Net Margin % 6.19
PRXL's Net Margin % is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. PRXL: 6.19 )
Ranked among companies with meaningful Net Margin % only.
PRXL' s Net Margin % Range Over the Past 10 Years
Min: 3.11  Med: 4.44 Max: 6.38
Current: 6.19
3.11
6.38
ROE % 25.21
PRXL's ROE % is ranked higher than
89% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. PRXL: 25.21 )
Ranked among companies with meaningful ROE % only.
PRXL' s ROE % Range Over the Past 10 Years
Min: 9.33  Med: 14.95 Max: 25.21
Current: 25.21
9.33
25.21
ROA % 7.29
PRXL's ROA % is ranked higher than
78% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.86 vs. PRXL: 7.29 )
Ranked among companies with meaningful ROA % only.
PRXL' s ROA % Range Over the Past 10 Years
Min: 3.4  Med: 5.96 Max: 7.99
Current: 7.29
3.4
7.99
ROC (Joel Greenblatt) % 52.84
PRXL's ROC (Joel Greenblatt) % is ranked higher than
79% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. PRXL: 52.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.14  Med: 42.99 Max: 58.04
Current: 52.84
21.14
58.04
3-Year Revenue Growth Rate 10.10
PRXL's 3-Year Revenue Growth Rate is ranked higher than
71% of the 140 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. PRXL: 10.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 13.9 Max: 19.1
Current: 10.1
5.3
19.1
3-Year EBITDA Growth Rate 18.90
PRXL's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. PRXL: 18.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRXL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -11.3  Med: 14.2 Max: 56.4
Current: 18.9
-11.3
56.4
3-Year EPS without NRI Growth Rate 21.10
PRXL's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. PRXL: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRXL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.8  Med: 21.1 Max: 40.6
Current: 21.1
-32.8
40.6
GuruFocus has detected 2 Warning Signs with Parexel International Corp $PRXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRXL's 10-Y Financials

Financials (Next Earnings Date: 2017-04-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PRXL Guru Trades in Q1 2016

Steven Cohen 69,900 sh (New)
Paul Tudor Jones 8,000 sh (New)
George Soros Sold Out
Joel Greenblatt Sold Out
Ken Fisher 2,336,981 sh (-0.78%)
Chuck Royce 300,800 sh (-3.99%)
Vanguard Health Care Fund 1,836,340 sh (-8.90%)
Jim Simons 146,700 sh (-60.46%)
» More
Q2 2016

PRXL Guru Trades in Q2 2016

Ken Fisher 2,337,002 sh (unchged)
Jim Simons Sold Out
Chuck Royce 293,600 sh (-2.39%)
Vanguard Health Care Fund 1,168,440 sh (-36.37%)
Paul Tudor Jones 4,800 sh (-40.00%)
Steven Cohen 20,200 sh (-71.10%)
» More
Q3 2016

PRXL Guru Trades in Q3 2016

Joel Greenblatt 64,743 sh (New)
Steven Cohen 103,800 sh (+413.86%)
Vanguard Health Care Fund 1,168,440 sh (unchged)
Chuck Royce 293,600 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 2,312,019 sh (-1.07%)
» More
Q4 2016

PRXL Guru Trades in Q4 2016

Paul Tudor Jones 82,309 sh (New)
Jana Partners 745,665 sh (New)
Joel Greenblatt 120,706 sh (+86.44%)
Steven Cohen Sold Out
Ken Fisher 2,244,444 sh (-2.92%)
Vanguard Health Care Fund 1,108,785 sh (-5.11%)
Chuck Royce 239,400 sh (-18.46%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8731
Compare:NYSE:BIO, NAS:BASI » details
Traded in other countries:PAX.Germany,
Parexel International Corp is a biopharmaceutical services company. The Company offers clinical research, clinical logistics, medical communications, and technology products and services to the pharmaceutical, biotechnology, and medical device industries.

Parexel is a global contract research organization that provides outsourced research and development services to pharmaceutical and biotechnology companies. Although the firm's clinical research services segment brings in the lion's share of revenue, Parexel also offers technical expertise and advice through its consulting and medical communications services segment, as well as information technology solutions through its Perceptive Informatics segment.

Ratios

vs
industry
vs
history
PE Ratio 22.52
PRXL's PE Ratio is ranked higher than
64% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.70 vs. PRXL: 22.52 )
Ranked among companies with meaningful PE Ratio only.
PRXL' s PE Ratio Range Over the Past 10 Years
Min: 6.5  Med: 25.92 Max: 42.45
Current: 22.52
6.5
42.45
Forward PE Ratio 16.45
PRXL's Forward PE Ratio is ranked higher than
88% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. PRXL: 16.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.52
PRXL's PE Ratio without NRI is ranked higher than
65% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. PRXL: 22.52 )
Ranked among companies with meaningful PE Ratio without NRI only.
PRXL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.5  Med: 25.91 Max: 42.45
Current: 22.52
6.5
42.45
Price-to-Owner-Earnings 19.27
PRXL's Price-to-Owner-Earnings is ranked higher than
77% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.53 vs. PRXL: 19.27 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PRXL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.66  Med: 22.29 Max: 256.94
Current: 19.27
9.66
256.94
PB Ratio 6.00
PRXL's PB Ratio is ranked lower than
71% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.38 vs. PRXL: 6.00 )
Ranked among companies with meaningful PB Ratio only.
PRXL' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.46 Max: 8
Current: 6
0.98
8
PS Ratio 1.37
PRXL's PS Ratio is ranked higher than
83% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.29 vs. PRXL: 1.37 )
Ranked among companies with meaningful PS Ratio only.
PRXL' s PS Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.17 Max: 1.77
Current: 1.37
0.33
1.77
Price-to-Free-Cash-Flow 16.04
PRXL's Price-to-Free-Cash-Flow is ranked higher than
69% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.41 vs. PRXL: 16.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PRXL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.42  Med: 19.45 Max: 3775
Current: 16.04
9.42
3775
Price-to-Operating-Cash-Flow 11.79
PRXL's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.08 vs. PRXL: 11.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PRXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.13  Med: 14.33 Max: 2776
Current: 11.79
5.13
2776
EV-to-EBIT 15.10
PRXL's EV-to-EBIT is ranked higher than
72% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.11 vs. PRXL: 15.10 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.1 Max: 84.6
Current: 15.1
5.9
84.6
EV-to-EBITDA 10.77
PRXL's EV-to-EBITDA is ranked higher than
71% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.75 vs. PRXL: 10.77 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.1 Max: 19.5
Current: 10.77
4.3
19.5
PEG Ratio 1.01
PRXL's PEG Ratio is ranked higher than
92% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.93 vs. PRXL: 1.01 )
Ranked among companies with meaningful PEG Ratio only.
PRXL' s PEG Ratio Range Over the Past 10 Years
Min: 0.24  Med: 1.4 Max: 15.28
Current: 1.01
0.24
15.28
Shiller PE Ratio 39.53
PRXL's Shiller PE Ratio is ranked higher than
50% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.08 vs. PRXL: 39.53 )
Ranked among companies with meaningful Shiller PE Ratio only.
PRXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.29  Med: 52.88 Max: 124
Current: 39.53
23.29
124
Current Ratio 1.59
PRXL's Current Ratio is ranked lower than
70% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. PRXL: 1.59 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.08
Current: 1.59
1.21
3.08
Quick Ratio 1.59
PRXL's Quick Ratio is ranked lower than
63% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. PRXL: 1.59 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.63 Max: 3.08
Current: 1.59
1.21
3.08
Days Sales Outstanding 96.38
PRXL's Days Sales Outstanding is ranked lower than
84% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.89 vs. PRXL: 96.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.59  Med: 84.65 Max: 149.34
Current: 96.38
61.59
149.34
Days Payable 22.06
PRXL's Days Payable is ranked lower than
85% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. PRXL: 22.06 )
Ranked among companies with meaningful Days Payable only.
PRXL' s Days Payable Range Over the Past 10 Years
Min: 7.12  Med: 13.49 Max: 22.06
Current: 22.06
7.12
22.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.10
PRXL's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 133 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. PRXL: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.3  Med: -1.3 Max: 2.8
Current: 2.1
-7.3
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.33
PRXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
70% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.31 vs. PRXL: 1.33 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PRXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.31  Med: 2.21 Max: 8.33
Current: 1.33
1.31
8.33
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.85
PRXL's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
86% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.85 vs. PRXL: 0.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.19
PRXL's Price-to-Median-PS-Value is ranked lower than
58% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. PRXL: 1.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 0.86 Max: 3.46
Current: 1.19
0.33
3.46
Price-to-Peter-Lynch-Fair-Value 0.98
PRXL's Price-to-Peter-Lynch-Fair-Value is ranked higher than
94% of the 32 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. PRXL: 0.98 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
PRXL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.39  Med: 1.78 Max: 16.68
Current: 0.98
0.39
16.68
Earnings Yield (Greenblatt) % 6.61
PRXL's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 269 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.54 vs. PRXL: 6.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 5.9 Max: 16.9
Current: 6.61
1.2
16.9
Forward Rate of Return (Yacktman) % 27.02
PRXL's Forward Rate of Return (Yacktman) % is ranked higher than
88% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. PRXL: 27.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PRXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.8  Med: 19.4 Max: 33.6
Current: 27.02
3.8
33.6

More Statistics

Revenue (TTM) (Mil) $2,426
EPS (TTM) $ 2.80
Beta0.83
Short Percentage of Float6.34%
52-Week Range $51.16 - 72.32
Shares Outstanding (Mil)50.95

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 2,098 2,223 2,358
EPS ($) 3.20 3.82 4.63
EPS without NRI ($) 3.20 3.82 4.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.86%
Dividends per Share ($)
» More Articles for PRXL

Headlines

Articles On GuruFocus.com
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 13,149 Shares Mar 12 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 15,600 Shares Mar 04 2010 

More From Other Websites
PAREXEL Named a FlexJobs Top 100 Company to Watch for Telecommuting and Remote Jobs in 2017 Mar 13 2017
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 02 2017
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 28 2017
7:02 am PAREXEL appoints Simon Harford as CFO effective June 1, 2017 Feb 28 2017
PAREXEL International Appoints Simon Harford as Senior Vice President and Chief Financial Officer Feb 28 2017
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Feb 23 2017
PAREXEL International to Participate at Cowen & Co. Health Care Conference and Barclays Global... Feb 22 2017
Najarian: heavy call buying in one health care name Feb 15 2017
PAREXEL INTERNATIONAL CORP Financials Feb 14 2017
Parexel looks to cut down on human errors in clinical trials Feb 13 2017
PAREXEL Launches ClinPhone RTSM Mobile App to Improve Supply Management and Increase Patient Safety Feb 13 2017
Falling Earnings Estimates Signal Weakness Ahead for PAREXEL (PRXL) Feb 10 2017
Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer Feb 09 2017
PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report Feb 09 2017
PAREXEL International to Present at Leerink Partners Healthcare Conference Feb 07 2017
PAREXEL downgraded by Credit Suisse Feb 06 2017
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 03 2017
PAREXEL International Corp. :PRXL-US: Earnings Analysis: Q2, 2017 By the Numbers : February 3, 2017 Feb 03 2017
Edited Transcript of PRXL earnings conference call or presentation 2-Feb-17 3:00pm GMT Feb 02 2017
Parexel to make Georgia acquisition on heels of restructuring news Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)